Stone Run Capital’s Maravai LifeSciences MRVI Stock Holding History

Stone Run Capital’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,535	Closed	-$269K	–	62
2022 Q3	$269K	Sell	10,535 -4,500	-30%	-$113K	0.15%	49
2022 Q2	$427K	Sell	15,035 -40,250	-73%	-$1.27M	0.21%	50
2022 Q1	$1.96M	Sell	55,285 -3,500	-6%	-$117K	0.72%	39
2021 Q4	$2.47M	Buy	+58,785	New	+$2.38M	0.8%	37

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Stone Run Capital's MRVI Position: Q4 2022 in Review

Stone Run Capital sold out of Maravai LifeSciences (MRVI) in Q4 2022, closing a stake of 10,535 shares — an estimated $269K sold.

Stone Run Capital first reported a position in MRVI in Q4 2021 and held it in 4 quarters. The position peaked at $2.47M in Q4 2021. 212 funds tracked by Wall St. Rank hold MRVI as of Q4 2022.

Stone Run Capital reported no remaining Maravai LifeSciences position as of Q4 2022 after selling out during the quarter.
Stone Run Capital sold 10,535 Maravai LifeSciences shares in Q4 2022, an estimated $269K.
Stone Run Capital first reported a position in Maravai LifeSciences in Q4 2021 and held it in 4 quarters.
Stone Run Capital's Maravai LifeSciences position peaked at $2.47M in Q4 2021.
212 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2022.

Based on Stone Run Capital's 13F filing for Q4 2022, filed 14 Feb 2023.